Less than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it releases its initial guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The new guidelines recognises that excess weight is a long-term condition that can be managed with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, notes the body.
Skinny Jab Supply Crisis
Despite the current most favorable case, the manufacturing of these medications would only suffice for approximately 100 million people – under 10% of those who need them, according to the health organization.
The advice urges nations and manufacturers to expand access, via approaches like patent sharing.
A patent on a key compound – the main ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Drugs Work
These medications imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals reduce food intake.
Patients commonly start to lose weight after several weeks of commencing the regular doses.
Studies indicates people may see weight return a year later of discontinuing the treatment, as their normal food cravings come back.
To be above a healthy weight elevates your likelihood for experiencing diseases, such as diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the health agency.
